SEARCH

SEARCH BY CITATION

References

  • ANDERSON, G.P. (1993). Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator. Life Sci., 52, 21452160.
  • BALL, D.I., BRITTAIN, R.T., COLEMAN, R.A., DENYER, L.H., JACK, D., JOHNSON, M., LUNTS, L.H.C., NIALS, A.T., SHELDRICK, K.E. & SKIDMORE, I.F. (1991). Salmeterol, a novel, long-acting β2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br. J. Pharmacol., 104, 665671.
  • BARTON, E. & MORRIS, C. (2003). Mechanisms and strategies to counter muscle atrophy. J. Gerontol. Series A, 58, 923926.
  • BEITZEL, F., GREGOREVIC, P., RYALL, J.G., PLANT, D.R., SILLENCE, M.N. & LYNCH, G.S. (2004). β2-Adrenoceptor agonist fenoterol enhances functional repair of regenerating rat skeletal muscle after injury. J. Appl. Physiol., 96, 13851392.
  • BENDOTTI, C., VILLA, M. & SAMANIN, R. (1986). Further evidence of the inhibitory role of perifornical hypothalamic beta-adrenergic receptors in the feeding behavior of hungry rats. Life Sci., 38, 259266.
  • BENSON, D.W., FOLEY-NELSON, T., CHANCE, W.T., ZHANG, F.S., JAMES, J.H. & FISCHER, J.E. (1991). Decreased myofibrillar protein breakdown following treatment with clenbuterol. J. Surg. Res., 50, 15.
  • BERNSTEIN, D., FAJARDO, G., ZHAO, M., URASHIMA, T., POWERS, J., BERRY, G. & KOBILKA, B.K. (2005). Differential cardioprotective/cardiotoxic effects mediated by β-adrenergic receptor subtypes. Am. J. Physiol., 289, H2441H2449.
  • BRODDE, O.E. (1991). β1- and β2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol. Rev., 43, 203242.
  • BURNISTON, J.G., NG, Y., CLARK, W.A., COLYER, J., TAN, L.B. & GOLDSPINK, D.F. (2002). Myotoxic effects of clenbuterol in the rat heart and soleus muscle. J. Appl. Physiol., 93, 18241832.
  • BURNISTON, J.G., TAN, L.B. & GOLDSPINK, D.F. (2005). β2-Adrenergic receptor stimulation in vivo induces apoptosis in the rat heart and soleus muscle. J. Appl. Physiol., 98, 13791386.
  • BUSQUETS, S., FIGUERAS, M.T., FUSTER, G., ALMENDRO, V., MOORE-CARRASCO, R., AMETLLER, E., ARGILES, J.M. & LOPEZ-SORIANO, F.J. (2004). Anticachetic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res., 64, 67256735.
  • CHEN, K.D. & ALWAY, S.E. (2000). A physiological level of clenbuterol does not prevent atrophy or loss of force in skeletal muscle of old rats. J. Appl. Physiol., 89, 606612.
  • DUNCAN, N.D., WILLIAMS, D.A. & LYNCH, G.S. (2000). Deleterious effects of chronic clenbuterol treatment on endurance and sprint exercise performance in rats. Clin. Sci., 98, 329347.
  • EMERY, P.W., ROTHWELL, N.J., STOCK, M.J. & WINTER, P.D. (1984). Chronic effects of β2-adrenergic agonists on body composition and protein synthesis in the rat. Biosci.Rep., 4, 8391.
  • FOERSTER, K., GRONER, F., MATTHES, J., KOCH, W.J., BIRNBAUMER, L. & HERZIG, S. (2003). Cardioprotection specific for the G protein Gi2 in chronic adrenergic signaling through β2-adrenoceptors. Proc. Natl. Acad. Sci. U.S.A., 100, 1447514480.
  • FOWLER, E.G., GRAVES, M.C., WETZEL, G.T. & SPENCER, M.J. (2004). Pilot trial of albuterol in Duchenne and Becker muscular dystrophy. Neurology, 62, 10061008.
  • GREGOREVIC, P., RYALL, J.G., PLANT, D.R., SILLENCE, M.N. & LYNCH, G.S. (2005). Chronic fenoterol administration impairs cardiac function in adult but not old rats. Am. J. Physiol., 289, H344H349.
  • GUHAN, A.R., COOPER, S., OBORNE, J., LEWIS, S., BENNETT, J. & TATTERSFIELD, A.E. (2000). Systemic effects of formoterol and salmeterol: a dose–response comparison in healthy subjects. Thorax, 55, 650656.
  • HUANG, H., GAZZOLA, C., PEGG, G.G. & SILLENCE, M.N. (2000). Differential effects of dexamethasone and clenbuterol on rat growth and on β2-adrenoceptors in lung and skeletal muscle. J. Animal Sci., 78, 604608.
  • JACKMAN, R.W. & KANDARIAN, S.C. (2004). The molecular basis of skeletal muscle atrophy. Am. J. Physiol., 287, C834C843.
  • JEPPSSON, A.B., KÄLLSTRÖM, B.L. & WALDECK, B. (1992). Studies on the interaction between formoterol and salmeterol in guinea-pig trachea in vitro. Pharmacol. Toxicol., 71, 272277.
  • JOHNSON, M., BUTCHERS, P.R., COLEMAN, R.A., NIALS, A.T., STRONG, P., SUMNER, M.J., VARDEY, C.J. & WHELAN, C.J. (1993). The pharmacology of salmeterol. Life Sci., 52, 21312143.
  • KILTS, J.D., GERHARDT, M.A., RICHARDSON, M.D., SREERAM, G., MACKENSEN, G.B., GROCOTT, H.P., WHITE, W.D., DAVIS, R.D., NEWMAN, M.F., REVES, J.G., SCHWINN, D.A. & KWATRA, M.M. (2000). β2-Adrenergic and several other G protein-coupled receptors in human atrial membranes activate both Gs and Gi. Circ. Res., 87, 705709.
  • KIM, Y.S., SAINZ, R.D., SUMMERS, R.J. & MOLENAAR, P. (1992). Cimaterol reduces beta-adrenergic receptor density in rat skeletal muscles. J. Animal. Sci., 70, 115122.
  • KISSEL, J.T., MCDERMOTT, M.P., MENDELL, J.R., KING, W.M., PANDYA, S., GRIGGS, R.C. & TAWIL, R. (2001). Randomized, double-blind, placebo controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology, 57, 14341440.
  • KISSEL, J.T., MCDERMOTT, M.P., NATARAJAN, R., MENDELL, J.R., PANDYA, S., KING, W.M., GRIGGS, R.C. & TAWIL, R. (1998). Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. Neurology, 50, 14021406.
  • LINDÉN, A., BERGENDAL, A., ULLMAN, A., SKOOGH, B.E. & LÖFDAHL, C.G. (1993). Salmeterol, formoterol, and salbutamol in the isolated guinea-pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax, 48, 547553.
  • LÖFDAHL, C.G. & SVEDMYR, N. (1989). Formoterol fumarate, a new β2-adrenoceptor agonist. Allergy, 44, 264271.
  • LYNCH, G.S. (2004). Emerging drugs for sarcopenia: age-related muscle wasting. Expert Opin. Emerging Drugs, 9, 345361.
  • LYNCH, G.S., HINKLE, R.T. & FAULKNER, J.A. (2000). Power output of fast and slow skeletal muscles ofmdx (dystrophic) and control mice after clenbuterol treatment. Exp. Physiol., 85, 295299.
  • MALTIN, C.A., HAY, S.M., DELDAY, M.L., SMITH, F.G., LOBLEY, G.E. & REEDS, P.J. (1987). Clenbuterol, a beta-agonist induces growth in innervated and denervated rat soleus muscle via apparently different mechanisms. Biosci. Rep., 7, 525532.
  • MARTINEAU, L., HORAN, M.A., ROTHWELL, N.J. & LITTLE, R.A. (1992). Salbutamol, a β2-adrenoceptor agonist, increases skeletal muscle strength in young men. Clin. Sci., 83, 615621.
  • MOORE, N.G., PEGG, G.G. & SILLENCE, M.N. (1994). Anabolic effects of the β2-adrenoceptor agonist salmeterol are dependent on route of administration. Am. J. Physiol., 267, E475E484.
  • PALMQVIST, M., IBSEN, T., MELLÉN, A. & LÖTVALL, J. (1999). Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. J. Respir. Crit. Care Med., 160, 244249.
  • PEARLMAN, D.S., KOTTAKIS, J., TILL, D. & CIOPPA, G.D. (2002). Formoterol delivered via a dry powder inhaler (Aerolizer): results from long-term clinical trials in children. Curr. Med. Res. Opin., 18, 445455.
  • PÖNICKE, K., HEINROTH-HOFFMANN, I. & BRODDE, O.E. (2003). Role of β1- and β2-adrenoceptors in hypertrophic and apoptotic effects of noradrenaline and adrenaline in adult rat ventricular cardiomyocytes. Naunyn-Schmiedeberg's Arch. Pharmacol., 367, 592599.
  • ROTHWELL, N.J., STOCK, M.J. & SUDERA, D.K. (1987). Changes in tissue blood flow and β-receptor density of skeletal muscle in rats treated with β2-adrenoceptor agonist clenbuterol. Br. J. Pharmacol., 90, 601607.
  • ROUX, F.J., GRANDORDY, B. & DOUGLAS, J.S. (1996). Functional and binding characteristics of long-acting β2-agonists in lung and heart. Am. J. Respir. Crit. CareMed., 153, 14891495.
  • RYALL, J.G., GREGOREVIC, P., PLANT, D.R., SILLENCE, M.N. & LYNCH, G.S. (2002). β2-Agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol. Am. J. Physiol., 283, R1386R1394.
  • RYALL, J.G., PLANT, D.R., GREGOREVIC, P., SILLENCE, M.N. & LYNCH, G.S. (2004). β2-Agonist administration reverses muscle wasting and improves muscle function in aged rats. J. Physiol., 555, 175188.
  • SILLENCE, M.N., MATTHEWS, M.L., SPIERS, W.G., PEGG, G.G. & LINDSAY, D.B. (1991). Effects of clenbuterol, ICI118551 and sotalol on the growth of cardiac and skeletal muscle and on β2-adrenoceptor density in female rats. Naunyn-Schmiedeberg's Arch. Pharmacol., 344, 449453.
  • SILLENCE, M.N., MOORE, N.G., PEGG, G.G. & LINDSAY, D.B. (1993). Ligand binding properties of putative β3-adrenoceptors compared in brown adipose tissue and in skeletal muscle membranes. Br. J. Pharmacol., 109, 11571163.
  • SMITH, W.N., DIRKS, A., SUGIURA, T., MULLER, S., SCARPACE, P. & POWERS, S.K. (2002). Alteration of contractile force and mass in the senescent diaphragm with β2-agonist treatment. J. Appl. Physiol., 92, 941948.
  • SNEDDON, A.A., DELDAY, M.I. & MALTIN, C.A. (2000). Ame-lioration of denervation-induced atrophy by clenbuterol is associated with increased PKC-α activity. Am. J. Physiol., 279, E188E195.
  • SOLIS-COHEN, S. (1900). The use of adrenal substance in the treatment of asthma. J. Am. Med. Assoc., 34, 11641166.
  • WALDECK, B. (1996). Some pharmacodynamic aspects on long-acting β-adrenoceptor agonists. Gen. Pharmac., 27, 575580.
  • XIAO, R.P., AVDONIN, P., ZHOU, Y.Y., CHENG, H., AKHTER, S.A., ESCHENHAGEN, T., LEFKOWITZ, R.J., KOCH, W.J. & LAKATTA, E.G. (1999). Coupling of β2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ. Res., 84, 4352.
  • ZEMAN, R.J., PENG, H., DANON, M.J. & ETLINGER, J.D. (2000). Clenbuterol reduces degeneration of exercised or aged dystrophic (mdx) muscle. Muscle Nerve, 23, 521528.